Holen Sie sich die Stockscreener-App
14.59
2.08%
-0.31
Handel nachbörslich:
14.59
Schlusskurs vom Vortag:
$14.90
Offen:
$14.36
24-Stunden-Volumen:
31,695
Relative Volume:
0.03
Marktkapitalisierung:
$65.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.77M
KGV:
-19.99
EPS:
-0.73
Netto-Cashflow:
$-17.36M
1W Leistung:
-0.48%
1M Leistung:
-7.83%
6M Leistung:
+86.81%
1J Leistung:
+115.19%
1-Tages-Spanne:
$14.32
$15.35
1-Wochen-Bereich:
$14.10
$16.00
52-Wochen-Spanne:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Vergleichen Sie INKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
14.59 | 67.39M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
Will MiNK Therapeutics Inc. (6Q40) stock see insider accumulationJuly 2025 Momentum & Weekly Stock Performance Updates - newser.com
How to escape a deep drawdown in MiNK Therapeutics Inc.Fed Meeting & Real-Time Sentiment Analysis - newser.com
Why MiNK Therapeutics Inc. stock is popular among millennialsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Is MiNK Therapeutics Inc. (6Q40) stock undervalued historicallyAnalyst Upgrade & Weekly Return Optimization Plans - newser.com
Tools to assess MiNK Therapeutics Inc.’s risk profileJuly 2025 Summary & Free Daily Entry Point Trade Alerts - newser.com
MiNK Therapeutics Inc. stock prediction for this weekQuarterly Market Summary & Technical Pattern Recognition Alerts - newser.com
Evaluating MiNK Therapeutics Inc. with trendline analysisQuarterly Earnings Summary & High Yield Stock Recommendations - newser.com
How MiNK Therapeutics Inc. (6Q40) stock moves in volatile trading sessions2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - newser.com
Risk vs reward if holding onto MiNK Therapeutics Inc.2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
What analysts say about MiNK Therapeutics Inc stockFundamental Stock Analysis & Fast Profit Portfolio Plans - earlytimes.in
Published on: 2025-10-03 05:09:10 - earlytimes.in
LakeShore Biopharma (NASDAQ:LSB) & MiNK Therapeutics (NASDAQ:INKT) Financial Survey - Defense World
MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board By Investing.com - Investing.com Nigeria
What analysts say about MiNK Therapeutics Inc 6Q40 stockQuarterly Earnings Review & Free Discover Massive Upside Stocks - earlytimes.in
MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board - Investing.com
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, FACS to Board of Directors - Quiver Quantitative
MiNK Therapeutics appoints Colonel (Ret.) John B. Holcomb to board of directors - MarketScreener
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors - GlobeNewswire
Military Medicine Legend with 780 Publications: MiNK Therapeutics Adds Combat Care Pioneer to Board - Stock Titan
MiNK Therapeutics Inc Stock Analysis and ForecastVolatility Index Analysis & Maximum Capital Growth - earlytimes.in
What drives MiNK Therapeutics Inc stock priceHigh Yield Income Stocks & Free Quantitative Trading Strategies - Early Times
MiNK Therapeutics CEO Dr. Jennifer Buell to Present at 10th Annual CAR-TCR Summit on iNKT Cell Therapies - Quiver Quantitative
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA - GlobeNewswire
First-in-Human Results: MiNK's Off-the-Shelf Cell Therapy Shows Disease Reversal in Immune Disorders - Stock Titan
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
4.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):